Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection.
Chemosurgical treatment of vaginal/cervical human papillomavirus (HPV) infection with 5-fluorouracil (5-FU) is limited by vulvar pain and dysuria resultant from leakage and vulvar/urethral tissue reaction to the 5-FU. Women with cervical HPV DNA identified by in situ hybridization on colposcopically directed biopsy were treated with topically applied 5% 5-FU cream. A fitted cervical cap was used to restrict exposure to 5-FU. Repeat biopsies and in situ hybridization at least 6 weeks after application failed to detect HPV DNA in 6 of 7 patients. In 1 case, 5-FU treatment was associated with a decreased intensity of detectable HPV DNA. No episodes of vulvar pain or dysuria occurred. 5-FU can be used in the treatment of cervical HPV with minimal side effects when applied utilizing a cervical cap.
Davila
G W
GW
Colorado Gynecology and Continence Center, Denver, CO 80218, USA.
Shroyer
K R
KR
D000287:Administration, Topical; D000328:Adult; D001706:Biopsy; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017403:In Situ Hybridization; D027383:Papillomaviridae / Q000235:genetics; D030361:Papillomavirus Infections / Q000188:drug therapy*; D014412:Tumor Virus Infections / Q000188:drug therapy*
D004279:DNA, Viral; D005472:Fluorouracil